Targeting the untargetable cancer—rezatapopt, an oral p53 reactivator
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across multiple solid tumor types ...
